Literature DB >> 22532309

Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Fabrice Muscari1, Jean-Pascal Guinard, Nassim Kamar, Jean-Marie Peron, Philippe Otal, Bertrand Suc.   

Abstract

BACKGROUND: Preoperative α-fetoprotein (AFP) levels may have an influence on disease-free survival (DFS) of patients after liver transplantation for hepatocellular carcinoma (HCC) located on a cirrhotic liver.
METHODS: Between 2000 and 2009, two groups were distinguished according to preoperative AFP level: normal-level group (<10 ng/ml) and increased-level group (>10 ng/ml). The increased-level group was further divided into three levels of preoperative AFP: 10-150, 150-500, and ≥ 500 ng/ml. DFS and recurrence rates were compared. All patients underwent transplantation using the preoperative 5/5 criteria.
RESULTS: Of the 122 patients in this study, 63 had normal and 59 had increased preoperative AFP. There were no differences between the two groups concerning perioperative or pathologic data. Those with an increased preoperative AFP level had a significantly shorter 5-year DFS, and their recurrence rate was higher than that of the normal AFP group. The 5-year DFS and recurrence rates were 71 and 4 %, respectively, for those with normal AFP; 57 and 10 %, respectively, for those with AFP 10-150 ng/ml; 46 and 24 %, respectively, for those with AFP 150-500 ng/ml; and 28 and 62 %, respectively, for those with AFP ≥ 500 ng/ml.
CONCLUSIONS: This study shows the prognostic value of preoperative AFP levels on DFS after a liver transplant for HCC in a population of patients undergoing transplantation with the same preoperative criteria.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22532309     DOI: 10.1007/s00268-012-1587-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  46 in total

1.  Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  J I Herrero; B Sangro; J Quiroga; F Pardo; M Herraiz; J A Cienfuegos; J Prieto
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

2.  Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Hadni-Bresson; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Laurent Sulpice; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges-Philippe Pageaux; Sebastien Dharancy; Olivier Chazouilleres; Daniel Cherqui; Christophe Duvoux
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

3.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study.

Authors:  J Figueras; L Ibañez; E Ramos; E Jaurrieta; J Ortiz-de-Urbina; F Pardo; J Mir; C Loinaz; L Herrera; P López-Cillero; J Santoyo
Journal:  Liver Transpl       Date:  2001-10       Impact factor: 5.799

5.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

6.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

7.  Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma.

Authors:  Noriyo Yamashiki; Jeffrey J Gaynor; Tomoaki Kato; K Rajender Reddy; Abhasnee Sobhonslidsuk; David Levi; Seigo Nishida; Juan Madariaga; Jose Nery; Eugene R Schiff; Andreas G Tzakis
Journal:  Am J Transplant       Date:  2004-05       Impact factor: 8.086

8.  Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.

Authors:  Christian Toso; Sonal Asthana; David L Bigam; A M James Shapiro; Norman M Kneteman
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Predictors and patterns of recurrence after resection of hepatocellular carcinoma.

Authors:  Charles Cha; Yuman Fong; William R Jarnagin; Leslie H Blumgart; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

10.  A single-center retrospective analysis of liver transplantation on 255 patients with hepatocellular carcinoma.

Authors:  Zheng-Xin Wang; Shao-Hua Song; Fei Teng; Gui-Hua Wang; Wen-Yuan Guo; Xiao-Min Shi; Jun Ma; You-Min Wu; Guo-Shan Ding; Zhi-Ren Fu
Journal:  Clin Transplant       Date:  2010 Nov-Dec       Impact factor: 2.863

View more
  6 in total

Review 1.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

Review 3.  Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.

Authors:  Arturo Soriano; Aranzazu Varona; Rajesh Gianchandani; Modesto Enrique Moneva; Javier Arranz; Antonio Gonzalez; Manuel Barrera
Journal:  World J Hepatol       Date:  2016-01-08

4.  Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): is this 50-year biomarker still up-to-date?

Authors:  Fabrice Muscari; Charlotte Maulat
Journal:  Transl Gastroenterol Hepatol       Date:  2020-10-05

5.  The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma.

Authors:  Eun-Ran Park; Sang-Bum Kim; Jee-San Lee; Yang-Hyun Kim; Dong-Hyoung Lee; Eung-Ho Cho; Sun-Hoo Park; Chul Ju Han; Bu-Yeo Kim; Dong Wook Choi; Young Do Yoo; Ami Yu; Jae Won Lee; Ja June Jang; Young Nyun Park; Kyung-Suk Suh; Kee-Ho Lee
Journal:  Cancer Med       Date:  2017-03-23       Impact factor: 4.452

6.  Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus.

Authors:  Xiaojing Ren; Yuanyuan Ji; Xuhua Jiang; Xun Qi
Journal:  Biosci Rep       Date:  2018-11-28       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.